Bispecific Antibody vs CAR-T (Heme) — Oncology Deal Terms Comparison
Market Analysis
In oncology, Bispecific Antibody and CAR-T (Heme) represent two of the most actively transacted modalities. At Phase 2, Bispecific Antibody deals carry a median total deal value of $2.2B with $348M upfront, compared to $2.0B total value and $309M upfront for CAR-T (Heme). The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Bispecific Antibody development milestones average $466M versus $414M for CAR-T (Heme). Commercial milestones are $652M for Bispecific Antibody and $580M for CAR-T (Heme). Royalty rates range from 12.9%-21.1% for Bispecific Antibody and 12.5%-20.4% for CAR-T (Heme).
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Bispecific Antibody and CAR-T (Heme) deal terms compare in oncology?
Which modality commands higher royalty rates: Bispecific Antibody or CAR-T (Heme)?
How do milestone structures differ between Bispecific Antibody and CAR-T (Heme)?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.